To date, the first‐generation ALK inhibitor crizotinib, second‐generation ALK inhibitors ceritinib, alectinib and brigatinib, and the third‐generation ALK inhibitor lorlatinib have been approved by the Food and Drug Administration (FDA) for the treatment of patients with lung cancer harbouring the EML4‐ALK translocation. This evidence concerns the gene EML4 and lung cancer.